THE COST-EFFECTIVENESS OF COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LUTEINIZING HORMONE RELEASING HORMONE AGONIST IN MEN WITH METASTATIC PROSTATE CANCER
The Journal of Urology, ISSN: 0022-5347, Vol: 174, Issue: 2, Page: 547-552
2005
- 29Citations
- 31Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations29
- Citation Indexes29
- 29
- CrossRef24
- Captures31
- Readers31
- 31
Article Description
Combined androgen blockade therapy (CAB) has been shown to have a small survival advantage over luteinizing hormone releasing hormone LH-RH agonists (LH-RHa) alone in men with metastatic prostate cancer. The goal of this study was to assess the cost-effectiveness of CAB with bicalutamide and LH-RH agonist therapy to LH-RH agonist therapy alone.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022534701683046; http://dx.doi.org/10.1097/01.ju.0000165569.48372.4c; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=22144444165&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16006889; http://www.jurology.com/doi/10.1097/01.ju.0000165569.48372.4c; https://dx.doi.org/10.1097/01.ju.0000165569.48372.4c; https://www.auajournals.org/doi/10.1097/01.ju.0000165569.48372.4c
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know